This clinical trial is focused on studying the effects of a treatment for Sjögren’s syndrome, a condition where the body’s immune system mistakenly attacks its own moisture-producing glands, leading to symptoms like dry mouth and eyes. The treatment being tested is called ianalumab (also known by its code name VAY736), which is a type of medication known as a monoclonal antibody. This medication is designed to target specific parts of the immune system to help reduce the symptoms of the disease. In this study, some participants will receive ianalumab, while others will receive a placebo, which looks like the treatment but does not contain the active medication.

The purpose of the study is to determine if ianalumab is more effective than a placebo in improving the condition of patients with active Sjögren’s syndrome. Participants in the study will receive the treatment or placebo through an injection under the skin, known as a subcutaneous injection, over a period of 52 weeks. Throughout the study, participants will be monitored to assess changes in their symptoms and overall health.

This trial aims to provide valuable information on the safety and effectiveness of ianalumab for treating Sjögren’s syndrome, potentially offering a new option for managing this condition. Participants will be closely observed by healthcare professionals to ensure their well-being and to gather data on how the treatment affects their symptoms over time.